Skip to main content

Table 1 Baseline data for patients with polymyositis and dermatomyositis and healthy controls.

From: Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis

  Patients*
n= 23
Median (range)
Healthy controls*
n= 12
Median (range)
Exercise
group*¤
n= 9
Median (range)
Control group*¤
n= 7
Median (range)
Sex
(female/male), n
17/6 9/3 8/1 6/1
Diagnosis
(PM/DM), n
11/12 NA 4/5 3/4
Age, years 58 (37 to 77) 51 (31 to 71) 60 (48 to 72) 58 (42 to 77)
Duration since
diagnosis, years
7 (1 to 33) NA 8 (1 to 13) 7 (2 to 33)
DMARD treatment
(GC/MTX/AZA/RITUX/MMF/CsA), n
13/9/5/2/1/1 NA 5/3/3/0/1/0 5/2/2/1/0/1
Daily GC dose, mg 5 (1 to 10) NA 5 (1 to 8) 2 (2 to 5)
MMT-8, 0 to 80 75 (42 to 80) NA 76 (42 to 79) 73 (57 to 77)
HAQ, 0.0 to 3.0 0.5 (0.0 to 1.8)1 NA 0.5 (0.0 to 1.4)1 0.5 (0.4 to 1.8)
CPK, μcat/l 2 (1 to 62)3 NA 2 (1 to 62)1 2 (1 to 4)1
Physician global
disease activity
VAS, 0 to 100
4 (8 to 16)2 NA 4 (0 to 14)1 2 (0 to 10)1
Patient global
disease activity
VAS, 0 to 100
39 (0 to 88)1 NA 24 (0 to 72)1 42 (3 to 77)
MITAX, 0 to 1.0 0.1 (0.0 to 0.2)2 NA 0.1 (0.0 to 0.2) 0.1 (0.1 to 0.2)1
Muscle disease activity, VAS, 0 to 100 2 (0 to 8)2 NA 2 (0 to 8)1 2 (0 to 7)1
Physician global damage VAS, 0 to 100 18 (0 to 62)2 NA 22 (7 to 62)1 22 (10 to 49)1
Muscle damage
VAS, 0 to 100
11 (0 to 39)2 NA 10 (0 to 39)1 14 (9 to 31)1
  1. *Data in median (range) if not stated otherwise. ¤, Patients with reliable lactate levels at baseline were randomly assigned to an exercise group or a control group. AZA, Azathioprine; CPK, creatine phosphokinase (normal values <2.5 μcat/liter in women, <3.0 μcat/liter in men); CsA, Cyclosporine A; DMARD, disease modifying anti-rheumatic drugs; GC, Glucocorticoids; HAQ, Health Assessment Questionnaire; MITAX, myositis intention to treat activity index; MMF, Mycophenolate mofetil; MMT, manual muscle test; MTX, Methotrexate; NA, not assessed; PM/DM, polymyositis/dermatomyositis; RITUX, Rituximab; VAS, visual analogue scale. 1, One missing datum; 2, Two missing data; 3, Three missing data. *, No statistical difference in any of the variables between groups; patients vs HC and EG vs CG assessed by Mann-Whitney U-test (P <0.05).